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Abstract
Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells
(mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica
vaginalis. The exact prevalence is unknown but it is estimated that mesotheliomas represent less
than 1% of all cancers. Its incidence is increasing, with an expected peak in the next 10–20 years.
Pleural malignant mesothelioma is the most common form of mesothelioma. Typical presenting
features are those of chest pain and dyspnoea. Breathlessness due to a pleural effusion without
chest pain is reported in about 30% of patients. A chest wall mass, weight loss, sweating, abdominal
pain and ascites (due to peritoneal involvement) are less common presentations. Mesothelioma is
directly attributable to occupational asbestos exposure with a history of exposure in over 90% of
cases. There is also evidence that mesothelioma may result from both para-occupational exposure
and non-occupational "environmental" exposure. Idiopathic or spontaneous mesothelioma can also
occur in the absence of any exposure to asbestos, with a spontaneous rate in humans of around
one per million. A combination of accurate exposure history, along with examination radiology and
pathology are essential to make the diagnosis. Distinguishing malignant from benign pleural disease
can be challenging. The most helpful CT findings suggesting malignant pleural disease are 1) a
circumferential pleural rind, 2) nodular pleural thickening, 3) pleural thickening of > 1 cm and 4)
mediastinal pleural involvement. Involvement of a multidisciplinary team is recommended to ensure
prompt and appropriate management, using a framework of radiotherapy, chemotherapy, surgery
and symptom palliation with end of life care. Compensation issues must also be considered. Life
expectancy in malignant mesothelioma is poor, with a median survival of about one year following
diagnosis.
Disease name and definition
Malignant mesothelioma is a cancer originating from the
lining cells (mesothelium) of the pleural and peritoneal
cavities, as well as the pericardium and the tunica vagina-
lis [1]. Its distribution may be uni- or multifocal or may
involve the lining cells in a continuous manner.
Epidemiology and aetiology
Before 1950, malignant mesothelioma was so rare that
some pathologists even questioned its existence [2]. How-
ever, the increasing use of asbestos after the second world
war led to the description of a causal relationship between
asbestos exposure and the development of mesothelioma
in 1960 [3]. Although its use was widely abandoned in the
western world in the 1980s, the long latency period
between exposure to asbestos and onset of mesothelioma,
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which can range from 15 to 60 years [4,5], meant that the
mortality rates from mesothelioma have continued to
rise. In the USA the annual deaths from mesothelioma
peaked at 3060 in 2002 and have subsequently declined,
however the incidence of mesothelioma will continue to
rise in the UK until it reaches a peak in about the year
2020 [6]. According to data gathered in the US Surveil-
lance Epidemiology and End Results programme for
1973–1992, there has been virtually a constant rate of
mesothelioma in females but a consistently higher rate for
males. In the 1960s a mesothelioma register was set up in
the UK to systematically record the mortality rates from
mesothelioma and to try to identify the incidence of
tumour development without known occupational expo-
sure. It is predicted that around 90,000 deaths will occur
from mesothelioma by 2050, with 65,000 of these occur-
ring from 2002 onwards [7].
Asbestos is a naturally occurring fibrous silicate, and the
risk of developing mesothelioma depends on the expo-
sure to different types of the asbestos mineral fibre. The
main asbestos mineral groups are serpentine fibres, which
are long and curly, or amphibole fibres which are straight
and rod-like. This distinction is important as the serpen-
tine fibre shape is more easily cleared from the respiratory
tract. Epidemiologic data suggests that the amphibole,
crocidolite, is associated with the highest risk of mesothe-
lioma [8] and that the serpentine fibre, chrysotile has the
lowest. The diagnosis of mesothelioma is directly attribut-
able to occupational asbestos exposure; however there is
evidence that mesothelioma may result from both para-
occupational exposure (e.g.: women having laundered
their husband's overalls) and non-occupational "environ-
mental" exposure [9]. Idiopathic or spontaneous mes-
othelioma can also occur in the absence of any exposure
to asbestos in both animals [10] and humans [8], and a
recent review suggests a spontaneous mesothelioma rate
in humans of around one per million [11].
Non-asbestos mineral fibres have also been shown to
induce mesothelioma, such as erionite found in certain
areas of Turkey [12] or tremolite in north-western Greece
[13], and whilst not specifically mined for commercial
purposes, tremolite is often found as a contaminant of
chrysotile asbestos and has been causally linked with an
increased risk of mesothelioma [14]. The role of Simian
virus (SV-40) in the pathogenesis of mesothelioma is
more controversial; SV-40 was found to contaminate
polio vaccines in the 1950s and 60s in the UK, and
although it has been suggested that it is a causative factor
in the development of mesothelioma [15-17], recent stud-
ies have found no link [18-20].
Clinical description
Mesothelioma is primarily a disease of adults and usually
presents in the fifth to seventh decades, and 70–80% of
cases occur in men. Those diagnosed between the ages of
20 to 40 years usually have a history of childhood expo-
sure [1]. Typical presenting features are those of chest
pain, dyspnoea or both [11,21], and in one series up to a
third of patients presented with breathlessness due to a
pleural effusion without chest pain [22]. When it occurs,
the chest pain tends to be dull or boring in nature, but a
pleuritic-type pain can occur in the presence of pleural
effusions. Involvement of the mediastinal structures is
well recognized but hoarseness of the voice and superior
vena caval obstruction only rarely causes major symp-
toms. Dysphagia can also occur but this is a late finding.
Unlike bronchogenic carcinomas, presentation with hae-
moptysis, lymphadenopathy and metastatic symptoms
are unusual. A chest wall mass, weight loss and sweating
are less common presentations, as is peritoneal mesothe-
lioma although involvement may be found in up to one
third of cases at autopsy. Presentation of peritoneal mes-
othelioma is with non-specific symptoms including loss
of appetite, nausea and vomiting, diarrhoea or constipa-
tion and occasionally ascites. Small bowel obstruction is
usually a late feature, and overall the prognosis of perito-
neal mesothelioma is worse than pleural mesothelioma
with a mean survival time of about 7 months [11].
Physical examination is usually unremarkable except for
signs of pleural effusion and pleural thickening due to
tumour infiltration. Finger clubbing is more common
than in benign asbestos related pleural disease, and can
occur in up to 30% of cases [23]. The tumour originates
mainly on the parietal pleura and spreads via the fissures,
to encase the lung surfaces. Infiltration of the pericardium
can result in signs of cardiac tamponade, and mesotheli-
oma can grow along needle tracks and incisions. Blood
tests can reveal an elevated erythrocyte sedimentation rate
(ESR) [24], and there have been isolated case reports of
mesothelioma associated with autoimmune haemolytic
anaemia [25].
Diagnosis and differential diagnosis
The combination of accurate history, examination, radiol-
ogy and the acquisition of pathology is essential in the
diagnosis of mesothelioma. A careful history of asbestos
exposure is essential, and the identification of at-risk
occupations are strong markers of exposure. However, the
delay between exposure and presentation may naturally
preclude accurate recall of occupational exposure and
working conditions which may have occurred up to 60
years previously.
In those patients with a pleural effusion, sampling of the
fluid for cytological examination is the first step in con-Orphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
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firming the diagnosis. Pleural fluid cytology is positive for
malignant cells in about a third of cases [1] and if the clin-
ical, radiological and cytological results support a diagno-
sis of mesothelioma then this can be accepted. However,
it is uncommon for the definitive diagnosis to be made on
pleural fluid cytology alone and pleural biopsy for tissue
diagnosis is therefore recommended. A contrast enhanced
computed tomogram (CT) scan is essential to both iden-
tify the extent of the disease, and help guide a percutane-
ous biopsy if the pleural fluid cytological analysis is not
sufficient.
Radiological findings
Radiological imaging is essential for the diagnosis, staging
and management of mesothelioma. X-ray, CT, magnetic
resonance imaging (MRI) and positron emission tomog-
raphy (PET) have all been used to evaluate the disease.
CT
Intravenous contrast-enhanced CT is the primary imaging
modality for suspected pleural malignant disease. CT
allows visualisation of the whole pleural surface and dia-
phragm and use of a 45–60 second scan delay enables the
pleural surfaces to be studied whilst still allowing assess-
ment of the mediastinal nodes [26]. A standard protocol
should include the liver and adrenal glands, but in cases
where there is a past history of abdominal or pelvic malig-
nancy, the scan should also include the lower abdomen
and pelvis [11].
Distinguishing malignant from benign pleural disease can
be challenging. The most helpful CT findings suggesting
malignant pleural disease are 1) a circumferential pleural
rind, 2) nodular pleural thickening, 3) pleural thickening
of > 1 cm and 4) mediastinal pleural involvement [27].
The specificities of these findings were 100%, 94%, 94%
and 88% respectively. The sensitivities were 41%, 51%,
36% and 56% respectively. The presence of bilateral pleu-
ral calcification on CT is uncommon in malignant mes-
othelioma [27]. A significant reduction in thoracic
volume seen on CT is more common, however, occurring
in up to 73% of cases according to some series [28]. Whilst
these features have a high positive predictive value,
absence of these signs does not reliably exclude the diag-
nosis of pleural malignancy.
MRI
MRI screening is not used routinely in the assessment of
malignant mesothelioma, however in patients with
potentially resectable disease, MRI can help to provide
additional staging information over and above CT. Using
gadolinium enhancement, MRI can improve the identifi-
cation of tumour extension into the diaphragm or chest
wall, allowing better assessment of the individual for sur-
gical treatment. MRI also is the imaging modality of
choice in those in whom intravenous iodinated contrast is
contraindicated [29].
PET
The standardized uptake value (SUV) in PET is a semi-
quantitative measure of the metabolic activity of a lesion
and the SUV is significantly higher in mesothelioma than
in other benign pleural diseases such as pleural plaques or
inflammatory pleuritis [29,30], and one study found PET
scanning to have a 96.8% sensitivity and an 88.5% specif-
icity at distinguishing benign from malignant pleural dis-
ease [31]. PET scanning has also increased the accuracy in
diagnosing mediastinal nodal metastases [30] and there-
fore the combination of metabolic and anatomical infor-
mation provided by PET makes it useful in the staging and
preoperative evaluation of mesothelioma. PET may also
help as a guide to the optimal site for CT guided pleural
biopsy, and there is evidence that changes in the fluorode-
oxyglucose (FDG) uptake within the tumour might indi-
cate response to treatment suggesting its role in the
assessment of response to both chemotherapy and
chemo-radiotherapy [32].
Staging and assessment of disease response
At least six different staging systems have been suggested
for malignant mesothelioma, but none have been accu-
rately shown to predict survival. Currently, a TNM staging
system (Table 1) similar to that used in non-small cell
lung carcinoma has been proposed by the International
Mesothelioma Interest Group (IMIG) [33].
Tumour response to treatment is an important surrogate
for patient benefit. The World Health Organization
(WHO) criteria for tumour response were most useful for
measuring bi-dimensional lesions, whereas the irregular
growth pattern of mesothelioma as a rind around the
chest wall makes these criteria poorly applicable [34].
More recently, the Response Evaluation Criteria in Solid
Tumours (RECIST) [35] uses a uni-dimensional measure-
ment of tumour size to assess response, but this is based
on the assumption that tumours are largely spherical, so
again there are limitations to the applicability of this tech-
nique in the assessment of malignant mesothelioma.
A modified RECIST criteria has now been published, how-
ever, with particular reference to malignant mesothelioma
[36]. Assessment of response to treatment is now made by
measuring uni-dimensional tumour thickness perpendic-
ular to the chest wall in 2 sites at three different levels on
CT.
Pathological findings
According to the WHO classification, malignant mesothe-
lioma can be classified as epithelioid, sarcomatoid, or
biphasic based on tissue obtained by biopsy. The patho-Orphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
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logical diagnosis is reached with the aid of immunohisto-
chemistry to demonstrate the presence of mesothelial,
epithelial, or true sarcomatous differentiation in the
malignant cells [37]. The reported diagnostic yield from
CT guided biopsy varies from 60% with a single attempt
up to 85% with multiple attempts [38]. Ultimately, how-
ever, the highest yields are obtained with open or thoraco-
scopic pleural biopsy.
There is currently no individual immunohistochemical
mesothelial marker that provides 100% specificity and
high sensitivity for the diagnosis of malignant mesotheli-
Table 1: IMIG TNM staging system
Primary tumour (T)
T1a Tumour limited to the ipsilateral parietal including mediastinal and diaphragmatic pleura, no involvement of the visceral 
pleura
T1b Tumour involving the ipsilateral parietal including mediastinal and diaphragmatic pleura, scattered foci of tumour also 
involving the visceral pleura
T2 Tumour involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral pleura) with at 
least one of the following features:
• involvement of diaphragmatic muscle
• confluent visceral pleural tumour (including the fissures)
• extension of tumour from visceral pleura into the underlying pulmonary parenchyma
T3 Locally advanced but potentially resectable tumour; tumour involving all of the ipsilateral pleural surfaces (parietal, 
mediastinal, diaphragmatic and visceral pleura) with at least one of the following features:
• involvement of the endothoracic fascia
• extension into the mediastinal fat
• solitary, completely resectable focus of tumour extending into the soft tissues of the chest wall
• non transmural involvement of the pericardium
T4 Locally advanced technically unresectable tumour; tumour involving all of the ipsilateral pleural surfaces (parietal, 
mediastinal, diaphragmatic and visceral) with at least one of the following features:
• diffuse extension or multifocal masses of tumour in the chest wall with or without associated rib destruction
• direct transdiaphragmatic extension of tumour to the peritoneum
• direct extension of tumour to the contralateral pleura
• direct extension of tumour to one or more mediastinal organs
• direct extension of tumour into the spine: tumour extending through to the internal surface of the pericardium with or 
without a pericardial effusion
• tumour involving the myocardium
Lymph nodes (N)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes
N2 Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal mammary nodes
N3 Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral supraclavicular 
lymph nodes
Metastases (M)
Mx Presence of distant metastases cannot be assessed
M0 No distant metastasis
M1 Distant metastasis presentOrphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
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oma [37] and so a number of mesothelial and epithelial
markers have been developed. Clearly, distinguishing a
malignant pleural process from an inflammatory process
is a priority and immunohistochemistry has demon-
strated that mesothelioma frequently shows immunore-
activity for keratin, p53 and epithelial membrane antigen
(EMA) which is unusual for benign pleural disease.
Differentiating malignant mesothelioma from other
malignancies, however, can be more difficult as mesothe-
liomas, especially those of the epithelioid type, can mimic
several other tumours. Again, immunohistochemistry can
help in the differentiation of mesothelioma and markers
such as mesothelin, cytokeratin 5/6, calretinin, thrombo-
modulin and WT-1 have been used. The most specific and
sensitive markers for mesothelioma are mesothelin (in
epithelioid mesothelioma), calretinin and cytokeratin 5/
6. However, according to a recent review article, mesothe-
lin is positive in 27% of squamous cell carcinomas, and
calretinin and cytokeratin 5/6 can be raised in both squa-
mous cell carcinoma of the lung and adenocarcinoma of
both the lung and other sites [37]. Clearly there can be dif-
ficulty in making the diagnosis, and so usually a panel of
two positive and two negative markers will be sufficient to
confirm the presence of malignant mesothelioma.
Serum markers in the diagnosis of mesothelioma
Reliably diagnosing malignant mesothelioma early in the
disease is notoriously difficult due to the variability in
time to presentation from exposure in the disease.
Recently there has been much interest in the use of serum
markers for the diagnosis of the disease. The ideal serum
marker would be one that is able to offer: 1) early diagno-
sis, 2) identification of all the subtypes, 3) differentiation
of malignant mesothelioma from benign pleural disease
and other metastatic pleural malignancies, and 4) be able
to track response to therapy and predict survival. As yet no
such ideal marker exists, but studies have suggested the
use of osteopontin, mesothelin or megakaryocyte potenti-
ating factor in this role.
Osteopontin is a glycoprotein that is over-expressed in
lung, breast, colorectal, gastric and ovarian carcinomas
and in melanoma. Increased levels correlate with tumour
progression, invasion and metastases. Although increased
levels do not exclude other malignancies, recent data sug-
gest that osteopontin has great potential use as a marker
for mesothelioma [39] and has a positive predictive
power for mesothelioma equivalent to Ca-125 for ovarian
cancer. Studies have suggested a sensitivity and specificity
for mesothelioma of 77% and 85% respectively [40].
Mesothelin is a membrane bound glycoprotein expressed
by mesothelial cells and over expressed in malignancy,
especially mesothelioma [41]. Soluble mesothelin related
proteins (SMRP) are serum proteins thought to be
released by alternative splicing of the mesothelin protein
and thereby preventing adherence to cell membranes.
Serum concentrations are increased in malignant mes-
othelioma, and therefore this protein is a potential serum
marker for the disease [42]. However, although most
patients with mesothelioma have raised serum levels of
SMRP, giving a sensitivity of between 80–83% and specif-
icity between 80–100% [43-45], it is mostly associated
with the epithelioid sub-type, leading to difficulties in
identifying the other sub-types of mesothelioma, espe-
cially sarcomatoid, using this marker alone [46]. Never-
theless a commercially available FDA-approved assay,
MESOMARK (Fujirebio Diagnostics Inc, Malvern, PA,
USA), has been recently approved for use in the monitor-
ing of disease in epithelioid and biphasic mesothelioma,
and data seems to support its usefulness [47].
Megakaryocyte Potentiating Factor (MPF) is secreted by
cells of several mesothelioma cell lines. In recent studies,
MPF was elevated in 91% of 56 malignant mesothelioma
patients compared with controls, and levels returned to
normal after surgery in patients with peritoneal mesothe-
lioma [46,48]. This might make MPF useful in the moni-
toring of treatment response in mesothelioma.
Management
Because there can be difficulty reaching a diagnosis of
mesothelioma despite radiology, cytology and biopsy, the
general management of patients with mesothelioma
should be under a multidisciplinary team including respi-
ratory physicians, oncologists, radiologists, palliative care
physicians and lung cancer specialist nurses. In addition,
once the diagnosis has been reached, there should be
close liaison with the patient's primary care physician,
and both the primary care physician and family should be
warned that, at least in the UK, a post mortem examina-
tion will usually be required after the death of a patient
with mesothelioma.
The general treatment strategy of mesothelioma should
cover the following areas:
￿ Management of pleural effusions
￿ Radiotherapy to intervention sites
￿ Suitability for radical surgery
￿ Suitability for clinical trial entry and chemotherapy
￿ Compensation issues
￿ Palliation of symptoms and end-of-life careOrphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
Page 6 of 11
(page number not for citation purposes)
Management of pleural effusions
Management of malignant pleural effusions begins with
therapeutic thoracocentesis, which assesses the response
of dyspnoea to fluid removal. If symptoms do not
respond to thoracocentesis, alternative causes of dysp-
noea should be sought such as pulmonary thromboem-
bolic disease, or lymphangitis carcinomatosis. Early,
successful management on pleural effusions with pleu-
rodesis is essential for the palliation of symptoms and the
prevention of a trapped lung. However with repeated tho-
racocentesis, the pleural fluid may undergo loculation
making it difficult to drain subsequently and also the risk
of pleural infection increases. If a conclusive diagnosis has
been made, chemical pleurodesis can be performed via a
small bore intercostal chest drain (9–14F), which has
equivalent success rates to larger bore chest drains with
the added benefit of patient comfort [49,50]. The ideal
sclerosing agent is sterile talc, with success rates between
70 and 96% [50-52], although care must be taken to
ensure the talc particles are of the optimal calibration to
prevent the rare risk of adult respiratory distress syndrome
(ARDS) [53].
If a firm diagnosis is yet to be made, and the patient is fit
enough for surgery, then thoracoscopy is an extremely
useful technique in the management of suspected malig-
nant pleural effusions. This procedure allows visualisa-
tion of the pleural surface, enables histological sampling
for diagnosis and allows complete drainage of the effu-
sion followed by pleurodesis via talc poudrage.
In patients with a trapped lung, or in whom pleurodesis
has failed, a pleuro-peritoneal shunt can be considered.
Whilst symptoms can improve in over 90% of patients,
complications (including shunt occlusion and infection)
occur in 15% and therefore their use is diminishing [54].
More recently, an ambulatory pleural drainage system
(Pleurx Pleural Catheter, Denver Biomedical Inc, USA) has
been developed. This system enables the patient to con-
trol the pleural effusion at home by means of a long-term
drainage catheter and vacuum bottles. This might help
patients with trapped lungs as it both avoids the need for
surgical intervention, and palliates dyspnoea [55].
Radiotherapy
Palliative radiotherapy
Radiotherapy can be used to control local tumour growth
and occasionally causes regression of disease, but there is
no evidence that radiotherapy alone affects survival [56].
It has, however, been shown to be helpful in the palliation
of pain [57], and approximately half the patients treated
with palliative radiotherapy derive some benefit [58]. It
also appears that short courses of radiotherapy (for exam-
ple 20 Gy in 5 fractions) are as effective as longer courses
such as 30 Gy in 10+ fractions [59], although there is a
total dose response effect [60]. Unfortunately, radiother-
apy is rarely helpful in either the palliation of dyspnoea or
the management of symptoms of mediastinal infiltration
such as superior vena caval obstruction (SVCO), and alter-
native methods of treatment such as SVC stenting should
be sought [11,61].
Radical radiotherapy as a single modality
Whilst hemithorax irradiation may provide symptomatic
benefit, no studies have shown that it prolongs survival
[61]. Mesothelioma can involve large areas of the pleural
cavity and use of radical radiotherapy over large fields
places a range of organs such as lungs, liver, spinal cord or
heart at a significant risk of dose related damage. As a
result, a recent Cochrane review found no randomised
clinical trial evidence to support the use of radical radio-
therapy alone (or in combination with other treatment
modalities) in mesothelioma [62], and this treatment
option has been shown to confer a significant mortality,
with rates as high as 17% in one series [59].
Radiotherapy as part of multimodality treatment
Failure to increase survival using single treatment modal-
ities has led to a multimodality approach to treatment in
mesothelioma. Combining debulking surgery with radio-
therapy is the cornerstone of this approach and can both
reduce systemic recurrence and influence the natural his-
tory of the disease [63,64]. Typically, hemithorax radio-
therapy is combined with extra pleural pneumonectomy
(EPP – see later) and correctly staged patients with epithe-
lioid mesothelioma can have median survival rates of 33
months [65]. Due to the large, irregular nature of malig-
nant mesothelioma along with the close proximity of
other organs, a more directed modality of irradiation
which could help improve local tumour control whilst
limiting exposure to surrounding organs has been devel-
oped, known as intensity modulated radiotherapy (IMRT)
[66]. Despite the possibilities for improved tumour con-
trol, however, IMRT still carries a potential risk of fatal
pulmonary toxicity in mesothelioma [67,68].
Prophylactic radiotherapy
Mesothelioma may seed malignant cells in procedure
scars. Whilst pain from these metastases is rare, they can
become uncomfortable, and evidence has suggested that
radiotherapy to intervention sites can prevent this compli-
cation [69,70]. Whilst this practice is recommended in
current guidelines [11], evidence is emerging that it
should only be offered to those patients who are sympto-
matic from these subcutaneous tumours as the radiother-
apy itself may have side effects [71,72].
Surgery
The role of surgery in the treatment of malignant mes-
othelioma is still uncertain. The three most common sur-Orphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
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gical procedures are surgical pleurodesis via video assisted
thoracoscopic surgery (VATS), debulking surgery (also
known as cytoreductive surgery or pleurectomy/decortica-
tion (P/D)) and extra pleural pneumonectomy (EPP).
This comprises en-bloc resection of the parietal pleura,
lung, pericardium and diaphragm and mediastinal nodes
[56]. P/D allows the removal of the visceral, parietal and
pericardial pleura as well as debulking the tumour and is
therefore less demanding, with mortality rates < 5% [73].
P/D has limitations, however, as it does not remove the
tumour completely, and the preservation of the ipsilateral
lung makes postoperative radiotherapy difficult due to the
risk of pulmonary side effects [74]. The impact of P/D on
overall survival is contentious, with some evidence sug-
gesting that P/D surgery via a VATS approach may provide
a survival benefit in patients with advanced disease not
suitable for EPP [75], whilst other studies do not clearly
distinguish the benefit of P/D over EPP [76].
EPP is a much more demanding procedure with morbid-
ity rates as high as 60% [77] and mortality rates of 4–9%
[11,78,79]. However, the pneumonectomy in EPP allows
the use of high dose hemithoracic radiotherapy, and this
combined treatment has been shown to reduce local
recurrence and prolong survival in early disease [65]. As a
result, as part of the trimodality approach to treatment
with surgery chemotherapy and radiotherapy, EPP has
arisen as the surgical treatment of choice, albeit without
clear randomised controlled trial evidence [78]. In order
to clarify this issue, a large randomized trial (Mesotheli-
oma And Radical Surgery (MARS)) is underway [80]. In
this trial, EPP is sandwiched between induction chemo-
therapy and radical radiotherapy. The control arm offers
full active tri-modality therapy, although the surgery is
limited to debulking surgery. In addition patients receive
the same induction chemotherapy and are given radio-
therapy to any drain or port sites.
Chemotherapy
The use of chemotherapy in malignant mesothelioma
aims to lengthen survival, improve quality of life and pro-
vide symptomatic relief. Currently, there is no single drug
or combination therapy that could be considered as
standard treatment for mesothelioma. A variety of single
agent and combination regimens have been tried in clini-
cal trials with response rates of between 0% and 45% [81].
A review of studies by Berghmans et al [82] revealed that
cisplatin was the most effective single agent for mesothe-
lioma, with carboplatin having similar activity, and in
combination with doxorubicin provided a response rate
superior to other regimens studied, although there was no
clear benefit in terms of survival. Single agent vinorelbine
and combination treatment MVP (mitomycin C, vinblas-
tine and cisplatin) have also been shown to provide good
symptom relief with acceptable toxicity [83-85].
Recently, there has been much interest in the use of the
antifolate pemetrexed (Alimta; Eli Lilly). Pemetrexed
exerts its effect by interrupting folate dependent metabolic
synthesis of purines and pyrimidines (the building blocks
of DNA and RNA), and a Cochrane review of the effective-
ness of combination treatment with cisplatin/pemetrexed
[81] suggests a survival benefit, albeit with increased tox-
icity which is reduced by the co-administration of vitamin
B12 and folate supplements. Much of the evidence sup-
porting the use of pemetrexed comes from a single study
[86] in which 331 patients, fully supplemented with vita-
min B12, demonstrated a median survival of 13.3 months
with combination pemetrexed/cisplatin compared to 10.0
months with cisplatin alone (p = 0.05). This was associ-
ated with a significant improvement in quality of life and
symptom relief compared to cisplatin alone [87]. Combi-
nation with carboplatin instead of cisplatin, however,
may be an alternative regimen which provides similar effi-
cacies and reduced side effects [88]. An alternative anti-
folate agent, raltitrexed, has also been shown to confer a
survival benefit in combination with cisplatin, with
median overall survival increasing from 8.8 months (CI
7.8–10.8) with cisplatin alone to 11.4 months (CI 10.1 to
15) with combination cisplatin-raltitrexed (p = 0.05) [89].
Although this study only demonstrated borderline signif-
icance, likely as a result of sample size, the results of these
trials mean that combination cisplatin and an antifolate
should be the reference regimen in mesothelioma. Recent
advances now favour the use of neoadjuvant chemother-
apy followed by EPP and radiation for malignant mes-
othelioma; Weder et al recently published their experience
of a prospective trial of neoadjuvant chemotherapy con-
sisting of cisplatin and gemcitabine followed by EPP,
demonstrating a median survival of 23 months [90]. Sim-
ilarly, Flores et al prospectively studied patients given
induction gemcitabine and cisplatin followed by EPP.
Median survival of all patients in the study was 19
months, but those patients who completed induction
chemotherapy and subsequently underwent EPP had a
median survival of 33.5 months [91].
As a result, all patients who are fit enough (ECOG per-
formance status 0–2) should have the opportunity to dis-
cuss the merits of chemotherapy in mesothelioma with an
oncologist [11], in the knowledge that there are no pub-
lished data which compares survival or symptom control
in patients treated with chemotherapy or best supportive
care only. The first such trial (MSO-1) [92] is complete,
and the preliminary results were published in abstract
form in 2007 [93]. These results suggest that the addition
of chemotherapy to active symptom control with best
supportive care did not infer a significant survival benefitOrphanet Journal of Rare Diseases 2008, 3:34 http://www.ojrd.com/content/3/1/34
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in mesothelioma, however this trial was started before the
emergence of pemetrexed.
Supportive and palliative care
Given that malignant mesothelioma has a poor overall
prognosis, referral of patients to specialist palliative care
services will be appropriate at some time in the disease
course. Most patients need palliation of symptoms early
on in the course of the disease and recognition of this by
the patient, family and primary care physician is essential
in the management of the patient with mesothelioma.
The use of a central lung cancer nurse specialist provides a
means by which the patient can gain access to the delivery
of care needed for this disease, through the following core
elements [11]:
￿ Communication
￿ Information
￿ Coordinated care between respiratory physicians, oncol-
ogists, radiologist and palliative care specialists
￿ Nursing care
￿ Accessibility
￿ Support
Prognosis and survival
Life expectancy in malignant mesothelioma is poor, with
median survival varying between 8 and 14 months [11].
The Cancer and Leukaemia Group B, and the European
Organization for Research and Treatment of Cancer have
analysed large numbers of patients enrolled in treatment
trials for mesothelioma and have identified the following
poor prognostic factors:
￿ Non-epithelioid histology
￿ Poor performance status
￿ Chest pain
￿ Age older than 75
￿ Male gender
￿ White blood cell count 8.3 × 109/L or greater
￿ Platelets greater than 400,000 μL
￿ LDH greater than 500 IU/L
The majority of patients who survive for more than 2 years
have epithelioid histology and death from mesothelioma
tends to be due to respiratory failure.
Compensation issues
Eligibility for compensation for mesothelioma may vary
from country to country. In the UK for example, a diagno-
sis of mesothelioma allows compensation via the Indus-
trial Injuries Disablement Benefit, War Pensions Scheme
or through a Common Law claim from the firm/firms
where the asbestos exposure occurred. Patients who can-
not identify occupational exposure to asbestos are not
entitled for compensation, however pathological confir-
mation of the diagnosis is not mandatory; establishing the
diagnosis and causation on the balance of probability is
sufficient, although an unequivocal diagnosis obviously
removes any cause for debate. Earlier this year, a new leg-
islation was made in the UK Child Maintenance and
Other Payments Act whereby dependants of persons with
mesothelioma became eligible to claim for lump-sum
compensation after death http://www.opsi.gov.uk/acts/
acts2008a.
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